This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
pharmaceuticals: Archive
Zoetis Gears Up to Report Q2 Earnings: Here's What to Expect
by Zacks Equity Research
ZTS eyes an earnings beat as companion animal drugs like Simparica Trio and Apoquel are expected to drive Q2 revenue gains.
ZTSPositive Net Change EXASPositive Net Change BNTXPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Regeneron Stock Rises on Q2 Earnings and Sales Beat, Eylea HD Sales Up
by Zacks Equity Research
REGN stock up as Q2 EPS jumps 12% on strong Eylea HD and Dupixent profits, beating revenue and earnings estimates.
REGNPositive Net Change SNYNegative Net Change BAYRYPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Jobs Shrink in the Summer of '25, Pre-Markets Lower
by Mark Vickery
+73K new jobs were filled last month, lower than the +100K expected. The Unemployment Rate ticked up 10 bps.
REGNPositive Net Change CVXNegative Net Change XOMPositive Net Change CLNegative Net Change
earnings interest-rate oil-energy pharmaceuticals staffing
JNJ or AZN: Which Pharma Giant is a Better Buy Post Q2 Results?
by Kinjel Shah
JNJ edges out AZN following Q2 results with raised guidance, stronger estimate revisions and a more attractive valuation.
AZNNegative Net Change JNJPositive Net Change
pharmaceuticals
Buy, Sell or Hold Pfizer Stock? Key Tips Ahead of Q2 Earnings
by Kinjel Shah
PFE eyes Q2 earnings beat as strength in Vyndaqel and Padcev is expected to offset declines from Eliquis, Ibrance and Prevnar.
PFENegative Net Change NVONegative Net Change LLYPositive Net Change BNTXPositive Net Change
pharmaceuticals
Stock Market News for Aug 1, 2025
by Zacks Equity Research
Wall Street closed lower on Thursday, pulled down by health care and real estate stocks.
MRKNegative Net Change LLYPositive Net Change
pharmaceuticals
Buy 5 Wide Moat Stocks to Enhance Your Portfolio Returns
by Nalak Das
Boost your portfolio with ADBE, DIS, INTU, ROL and JNJ as these five wide moat stocks poised for growth and strong returns.
JNJPositive Net Change DISPositive Net Change ADBENegative Net Change INTUNegative Net Change ROLPositive Net Change
business-services computers consumer-discretionary pharmaceuticals
BioCryst Pharmaceuticals Before Q2 Earnings: How to Play the Stock
by Ahan Chakraborty
BCRX gears up for Q2 results with Orladeyo growth in focus, but 2025 EPS forecasts dip as investors eye pipeline progress.
BCRXNegative Net Change IONSNegative Net Change NTLANegative Net Change
biotechnology biotechs earnings-preview medical pharmaceuticals
TEVA Q2 Earnings Beat, Revenues Miss on Lower Generics Sales
by Zacks Equity Research
TEVA tops Q2 earnings expectations as branded drugs shine, but revenues slip on weak generics and Japan exit.
JNJPositive Net Change TEVANegative Net Change ABBVPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
AbbVie Beats on Q2 Earnings & Sales, Stock Up on Raised '25 EPS View
by Zacks Equity Research
ABBV tops Q2 forecasts and lifts 2025 EPS outlook as Rinvoq and Skyrizi drive growth amid Humira's decline.
RHHBYPositive Net Change JNJPositive Net Change ABBVPositive Net Change
biotechs earnings medical pharmaceuticals
Bristol Myers Beats on Q2 Earnings and Sales, Raises '25 Sales View
by Zacks Equity Research
BMY's Q2 EPS and revenues beat estimates, powered by strong Growth portfolio sales and a lesser than expected decline in Legacy portfolio sales.
BMYNegative Net Change PFENegative Net Change EXELPositive Net Change BNTXPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Bausch Health Stock Falls on Q2 Earnings Miss, Revenues Beat
by Zacks Equity Research
BHC stock falls 6.3% as Q2 earnings miss estimates despite stronger sales and growth in key segments like Salix and Solta Medical.
DRRXNegative Net Change CRMDNegative Net Change BHCNegative Net Change ARVNNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Sanofi Q2 Earnings & Sales Miss, 2025 Top-Line View Raised, Stock Down
by Zacks Equity Research
SNY misses Q2 earnings and sales estimates but lifts 2025 sales outlook on strong Dupixent and vaccine momentum.
REGNPositive Net Change SNYNegative Net Change AZNNegative Net Change
pharmaceuticals
Company News for Jul 31, 2025
by Zacks Equity Research
Companies in The News Are: MO, AEP, GSK, EA
GSKPositive Net Change AEPNegative Net Change MONegative Net Change EAPositive Net Change
pharmaceuticals utilities
Ionis Beats on Q2 Earnings & Sales, Stock Up 5% on Raised '25 Outlook
by Zacks Equity Research
Ionis crushes Q2 estimates with EPS of $0.86 and sales of $452 million, lifting its 2025 revenue forecast and sending shares up 5%.
AZNNegative Net Change NVSPositive Net Change BIIBNegative Net Change IONSNegative Net Change
biotechs earnings medical pharmaceuticals
GSK Beats on Q2 Earnings & Sales, Stock Gains on '25 Outlook Raise
by Zacks Equity Research
GSK's Q2 earnings and revenues top forecasts, with Specialty Medicines and Vaccines driving growth and a raised 2025 outlook boosting shares.
GSKPositive Net Change JNJPositive Net Change VIRNegative Net Change
biotechs earnings medical pharmaceuticals vaccines
Alvotech Gears Up to Report Q2 Earnings: Here's What to Expect
by Zacks Equity Research
ALVO preps for Q2 results as investors eye early U.S. traction for Simlandi and Selarsdi, plus pipeline progress.
RDYNegative Net Change AMGNNegative Net Change TEVANegative Net Change ALVOPositive Net Change
biotechnology biotechs medical pharmaceuticals
NVO Stock Crashes 22% After 2025 View Cut: More Downside Ahead?
by Ahan Chakraborty
Novo Nordisk stock plunges 22% after slashing 2025 sales and profit outlooks, citing weak GLP-1 drugs' uptake and rising competition.
NVONegative Net Change LLYPositive Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
3 Genomics Stocks Worth Adding to Your Portfolio in 2025
by Ekta Bagri
CRISPR-based innovators like NTLA, EDIT and PRME are gaining traction as genomics reshapes the future of medicine and biotech
ILMNPositive Net Change BEAMNegative Net Change EDITPositive Net Change NTLANegative Net Change PRMEPositive Net Change CRSPNegative Net Change
biotechnology biotechs gene-editing gene-therapy genetics genomics medical pharmaceuticals
Merck Unveils Cost-Cutting Plan: Can it Create Long-Term Value?
by Kanishka Das
MRK targets $3B in annual savings by 2027 as it cuts jobs and refocuses investment ahead of Keytruda's 2028 patent cliff.
BMYNegative Net Change PFENegative Net Change MRKNegative Net Change VRNAPositive Net Change
pharmaceuticals
Will Collaboration With Bain Capital Help BMY Advance Its Pipeline?
by Ekta Bagri
Bristol Myers partners with Bain Capital to launch a new autoimmune-focused biotech, out-licensing five key immunology assets.
BMYNegative Net Change MRKNegative Net Change AMGNNegative Net Change
biotechnology biotechs medical pharmaceuticals
The Zacks Analyst Blog Highlights Broadcom, Berkshire Hathaway, Johnson & Johnson, Oil-Dri Corp. of America and Park Aerospace
by Zacks Equity Research
Broadcom, Berkshire Hathaway, and J&J headline a strong slate of stocks, with rising momentum in AI, insurance, and pharma growth drivers.
JNJPositive Net Change BRK.BPositive Net Change AVGOPositive Net Change PKEPositive Net Change ODCPositive Net Change
aerospace industrial-products insurance pharmaceuticals semiconductor
Top Analyst Reports for Broadcom, Berkshire Hathaway & Johnson & Johnson
by Mark Vickery
Broadcom gains on AI chip strength and VMware synergy, while JNJ and BRK.B ride momentum despite looming headwinds.
JNJPositive Net Change BRK.BPositive Net Change LVSNegative Net Change CLSPositive Net Change AVGOPositive Net Change PKEPositive Net Change OKTANegative Net Change ODCPositive Net Change
aerospace industrial-products insurance pharmaceuticals semiconductor
Merck Q2 Earnings Top, Sales Meet Estimates, 2025 View Narrowed
by Zacks Equity Research
MRK beats second-quarter estimates for EPS while matching the same for sales. The company trims its 2025 outlook.
AZNNegative Net Change MRKNegative Net Change VRNAPositive Net Change
earnings pharmaceuticals
INCY's Q2 Earnings & Revenues Beat Estimates on Higher Product Sales
by Zacks Equity Research
Incyte reports better-than-expected second-quarter 2025 results, beating both earnings and revenue estimates, driven by strong Jakafi and Opzelura sales.
NVSPositive Net Change LLYPositive Net Change BAYRYPositive Net Change INCYNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals